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INTRODUCTION
Hysteromyoma is benign monoclonal tumors of the 
uterine smooth muscle cells and consists of large 
amounts of extracellular matrix that contain collagen, 
fibronectin, and proteoglycan.[1] The prevalence of 
hysteromyoma varies between 5% and 65% depending 
on age, ethnicity, geographical region, and quality of 
imaging techniques.[2]
The majority of hysteromyomas are asymptomatic, 
however up to 20% cause menorrhagia, pelvic pain, 
and genitourinary symptoms.[3,4] Hysteromyomas 
are associated with 10% of infertility cases and are 
a sole cause of infertility in 1-3% of patients.[5] They 
can occur as single or multiple focal fibroids or can 
be diffuse. Hysteromyomas are most often diagnosed 
in the perimenopausal years. The incidence of 
hysteromyoma declines after menopause.
The mechanism for the development of 
hysteromyoma is poorly understood. Both genetic 
factors such as mutations and environmental 
factors have been implicated in the development 
of hysteromyoma.[6,7] According to literature data, 
more than 100 genes can take part in hysteromyoma 
formation.[8,9]
MATERIALS AND METHODS
Investigation of associations of polymorphic markers 
genes under study was pursued at sampling of 
1214 cases, among them, 227 are with hysteromyoma, 
and 987 persons of the control group. The sampling 
was women of Russian nationality coming from 
Russia Central Region and not being relatives. 
Clinic laboratory investigation was pursued based on 
gynecology department of perinatal center St. Joasaph 
Belgorod Regional Clinic Hospital. Patients with 
hysteromyoma were made an ultrasound investigation 
of pelvic organs, hysteroscopy with the following 
target biopsy of the lining of the uterus, and scrape 
histologic examination; there were applied general 
and laboratory study methods.
All the patients with hysteromyoma and the control 
group samples had typing of eight molecular and 
genetic markers: COMT c.186C>T (rs4633), FGFR1 
c.359-272C>T (rs2288696), FUSSEL18/SKOR2 
c.2917+4592C>G (rs1398217), EGF c.-2186T>C 
(rs3756261), INHBA g.41470093C>G (rs1079866), 
ZNF483 c.721+4952C>T (rs10441737), RXRG c.-
130-837T>C (rs466639), and FSHB g.30240178C>A 
(rs11031010).
ABSTRACT
Aim: The article highlights the bioinformatics analysis data of eight polymorphous loci among 569 patients with hysteromyoma 
and 981 women from the control group. Material and Methods: Investigation of associations of polymorphic markers genes 
under study was pursued at sampling of 1214 cases, among them, 227 are with hysteromyoma, and 987 persons of the control 
group. Results: It was found that the increased risk of hysteromyoma in women of Russia Central region is connected with 
the combination of the following molecular genetic markers: C rs4633 with C rs2288696 with 1398217 with G rs3756261 
with G rs1079866 and T rs10441737 (odds ratio [OR] = 2.28), and the protective effect has the combination of alleles 
T rs466639 with C rs1398217 and A rs11031010 (OR = 0.32). Conclusion: Thus, in the process of the research, it was 
found that the risk of hysteromyoma in women of the Central Black Soil Region of the Russian Federation, is raised by the 
combination of the molecular.
KEY WORDS: Bioinformatics, Genetic polymorphism, Hysteromyoma
Department of Biomedical Sciences, Belgorod State University, Belgorod 308015, Russia
*Corresponding author: Irina V. Ponomarenko, Department of Biomedical sciences, Belgorod State University, 85 Pobeda 
Street, Belgorod 308015, Russia. E-mail: Ponomarenko_i@bsu.edu.ru
Received on: 18-07-2017; Revised on: 29-08-2017; Accepted on: 14-09-2017
Access this article online
Website: jprsolutions.info ISSN: 0974-6943
Research Article
Irina V. Ponomarenko et al.
Journal of Pharmacy Research  | Vol 11 • Issue 10 • 2017 1215
Molecular genetic estimation of all the locuses was 
performed by the method of polymerase chain reaction 
of DNA synthesis using oligonucleotide primers and 
probes.[10] Genotyping of DNA markers is performed 
by the method of TaqMan probes detection according 
to data of level value relative to the fluorescence 
of each probe at “IQ5” amplificator with detecting 
system in real-time mode.
To estimate the correspondence of genotype 
distribution understudy to the expected one, and based 
on Hardy–Weinberg equilibrium, one used c2 test. 
Estimation of the role of genetic variants combinations 
in contraction of hysteromyoma is performed using 
the software APSampler using Markov chains Monte 
Carlo technique and Bayesian distribution-free 
statistics.[11]
RESULTS AND DISCUSSION
After examination of 569 women with hysteromyoma 
and 981 women from the control group, it was 
determined, that the control group is completely 
commeasurable with sampling of cases with 
hysteromyoma by gender, age, nationality, and place 
of birth, and by height and weight (Р > 0.05). Main 
characteristics of the studied groups are given in 
Table 1.
Examination of alleles concentration of genes 
polymorphic markers under study showed that for all 
the examined locuses in the group of patients with 
hysteromonia and in population sampling, empiric 
genotype distribution corresponded to the expected 
one at Hardy–Weinberg equilibrium (P > 0.05) 
(Table 2).
While using bioinformational approaches, it was 
determined that the combination of six genetic variants 
C COMT (rs4633) with C FGFR1 (rs2288696) 
with G FUSSEL18/SKOR2 (rs1398217) with 
G EGF (rs3756261) with G INHBA (rs1079866) and 
T ZNF483 (rs10441737) in the group of cases with 
hysteromyoma (8.56%) is much more often (2.2 times 
more) than in the control group (3.94%, P = 0.0003). 
These data testify about a great contribution of the 
combination of polymorphic genes variants rs4633 
with rs2288696 with rs1398217 with rs3756261 
with rs1079866 and rs10441737to hysteromyoma 
formation (odds ratio [OR]= 2.28).
The catechol-O-methyltransferase (COMT) 
catalyzes the transfer of a methyl group from 
S-adenosylmethionine to catecholamines including 
the neurotransmitters dopamine, epinephrine, and 
norepinephrine. This O-methylation results in one of 
the major degradative pathways of the catecholamine 
transmitters. In addition to its role in the metabolism 
of endogenous substances, COMT is important in the 
metabolism of catechol drugs used in the treatment 
of hypertension, asthma, and Parkinson disease. 
COMT is found in two forms in tissues, a soluble 
form (S-COMT) and a membrane-bound form 
(MB-COMT). The differences between S-COMT 
and MB-COMT reside within the N-termini. Several 
transcript variants are formed through the use of 
alternative translation initiation sites and promoters.[12]
The protein encoded by this gene is a member of the 
fibroblast growth factor receptor (FGFR) family, 
where amino acid sequence is highly conserved 
between members and throughout evolution. FGFR 
family members differ from one another in their 
ligand affinities and tissue distribution. A full-length 
representative protein consists of an extracellular region, 
composed of three immunoglobulin-like domains, a 
single hydrophobic membrane-spanning segment and a 
cytoplasmic tyrosine kinase domain. The extracellular 
portion of the protein interacts with fibroblast growth 
factors, setting in motion a cascade of downstream 
signals, ultimately influencing mitogenesis, and 
differentiation. This particular family member binds 
both acidic and basic fibroblast growth factors and is 
involved in limb induction. Mutations in this gene have 
been associated with Pfeiffer syndrome, Jackson-Weiss 
syndrome, Antley-Bixler syndrome, osteoglophonic 
dysplasia, and autosomal dominant Kallmann 
syndrome 2. Chromosomal aberrations involving this 
gene are associated with stem cell myeloproliferative 
disorder and stem cell leukemia lymphoma syndrome. 
Alternatively, spliced variants which encode different 
protein isoforms have been described; however, not all 
variants have been fully characterized.[13]
SKI family transcriptional corepressor 2 (FUSSEL18/
SKOR2) exhibits transcriptional repressor activity.[14]
Epidermal growth factor (EGF) encodes a member 
of the EGF superfamily. The encoded preproprotein 
is proteolytically processed to generate the 53 amino 
acid EGF peptide. This protein acts a potent mitogenic 
factor that plays an important role in the growth, 
proliferation, and differentiation of numerous cell 
types. This protein acts by binding with high affinity 
to the cell surface receptor, EGF receptor. Defects in 
this gene are the cause of hypomagnesemia type 4. 
Dysregulation of this gene has been associated 
with the growth and progression of certain cancers. 
Alternative splicing results in multiple transcript 
Table 1: Characteristics of the individuals from the 
case and control groups
Characteristics Cases Controls
Total 569 981
Age, years 41.20±9.05 43.1±7.7
Weight, kg 61.3±1.9 64.4±1.6
Height, cm 162.8±5.1 164.4±4.6
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variants at least one of which encodes a preproprotein 
that is proteolytically processed.[15]
The inhibin beta-A (INHBA) subunit joins the alpha-
subunit to form a pituitary follicle-stimulating hormone 
(FSH) secretion inhibitor. Inhibin has been shown to 
regulate gonadal stromal cell proliferation negatively 
and to have tumor-suppressor activity. In addition, 
serum levels of inhibin have been shown to reflect 
the size of granulosa cell tumors and can therefore 
be used as a marker for primary as well as recurrent 
disease. Because expression in gonadal and various 
extragonadal tissues may vary several folds in a tissue-
specific fashion, it is proposed that inhibin may be 
both a growth/differentiation factor and a hormone. 
Furthermore, the beta-A subunit forms a homodimer, 
activin A, and also joins with a beta-B subunit to form 
a heterodimer, activin AB, both of which stimulate FSH 
secretion.[14]
Zinc finger protein 483 (ZNF483) may be involved 
in transcriptional regulation.[16] Among patients with 
hysteromyoma, it was recorded the lowest frequency 
of combination alleles T RXRG (rs466639) with 
C FUSSEL18/SKOR2 (rs1398217) and A FSHB 
(rs11031010) (1.82%) compared to the control group 
(5.41%, P = 0.0003, OR = 0.32).
Retinoid X receptor gamma (RXRG) encodes a 
member of the RXRG family of nuclear receptors 
which are involved in mediating the antiproliferative 
effects of retinoic acid (RA). This receptor form 
dimers with the RA, thyroid hormone, and Vitamin 
D receptors increasing both DNA binding and 
transcriptional function on their respective response 
elements. This gene is expressed at significantly 
lower levels in nonsmall cell lung cancer cells. 
Alternatively, spliced transcript variants have been 
described.[17]
FSH, beta polypeptide encodes the beta-subunit of FSH. 
In conjunction with luteinizing hormone, FSH induces 
egg and sperm production. The pituitary glycoprotein 
hormone family includes FSH, luteinizing hormone, 
chorionic gonadotropin, and thyroid-stimulating 
hormone. All of these glycoproteins consist of an 
identical alpha-subunit and a hormone-specific beta-
subunit.[13]
Table 2: Summary information about the studied polymorphisms
Polymorphism Studied groups Minor allele MAF (%) HWE
χ2 P
COMT c. 186C>T
(rs4633)
Case T 52.12 0.41 >0.05
COMT c. 186C>T
(rs4633)
Control T 54.21 1.15 >0.05
FGFR1 c. 359-272C>T
(rs2288696)
Case T 27.27 0.52 >0.05
FGFR1 c. 359-272C>T
(rs2288696)
Control T 24.58 1.21 >0.05
FUSSEL18/SKOR2 
c.2917+4592C>G (rs1398217)
Case G 65.25 0.001 >0.05
FUSSEL18/SKOR2 
c.2917+4592C>G (rs1398217)
Control G 67.12 1.74 >0.05
EGF c.-2186T>C
(rs3756261)
Case C 27.865 0.30 >0.05
EGF c.-2186T>C
(rs3756261)
Control C 29.35 0.84 >0.05
INHBA g. 41470093C>G
(rs1079866)
Case G 9.74 0.31 >0.05
INHBA g. 41470093C>G
(rs1079866)
Control G 7.69 0.94 >0.05
ZNF483 c. 721+4952C>T
(rs10441737)
Case C 53.23 0.54 >0.05
ZNF483 c. 721+4952C>T
(rs10441737)
Control C 55.12 1.08 >0.05
RXRG c.-130-837T>C
(rs466639)
Case T 26.16 0.52 >0.05
RXRG c.-130-837T>C
(rs466639)
Control T 24.25 1.25 >0.05
FSHB g. 30240178C>A
(rs11031010)
Case A 6.84 0.34 >0.05
FSHB g. 30240178C>A
(rs11031010)
Control A 8.68 0.74 >0.05
MAF: Minor allele frequency, HWE: Hardy–Weinberg equilibrium. P values were calculated using the χ2 test
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CONCLUSION
Thus, in the process of the research, it was found that 
the risk of hysteromyoma in women of the Central 
Black Soil Region of the Russian Federation, is 
raised by the combination of the following molecular 
genetic markers: C rs4633 with C rs2288696 with 
G rs1398217 with G rs3756261 with G rs1079866 and 
T rs10441737 (OR = 2.28), and the combination of 
alleles has protective properties: T rs466639 with C 
rs1398217 and A rs11031010 (OR = 0.32).
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